International Online Medical Council (IOMC)

Citations Report

Journal of Next Generation Sequencing & Applications : Citations & Metrics Report

Articles published in Journal of Next Generation Sequencing & Applications have been cited by esteemed scholars and scientists all around the world. Journal of Next Generation Sequencing & Applications has got h-index 10, which means every article in Journal of Next Generation Sequencing & Applications has got 10 average citations.

Following are the list of articles that have cited the articles published in Journal of Next Generation Sequencing & Applications.

	2022	2021	2020	2019	2018
Year wise published articles	0	31	27	0	1
Year wise citations received	81	96	113	87	65

Journal total citations count	655
Journal impact factor	5.42
Journal 5 years impact factor	7.34
Journal cite score	6.34
Journal h-index	10
Journal h-index since 2018	8

Journal Impact Factor 2020 formula
IF= Citations(y)/{Publications(y-1)+ Publications(y-2)} Y= Year
Journal 5-year Impact Factor 2020 formula
Citations(2016 + 2017 + 2018 + 2019 + 2020)/ {Published articles(2016 + 2017 + 2018 + 2019 + 2020)}
Journal citescore
Citescore_y = Citations_y + Citations_y-1 + Citations_y-2 + Citations _y-3 / Published articles_y + Published articles_y-1 + Published articles_y-2 + Published articles _y-3

Important Citations

VodÃ¡k D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E. Sample-Index Misassignment Impacts Tumour Exome Sequencing. Scientific reports. 2018 Mar 28;8(1):5307. View at Publisher View at Google Scholar
Tsongalis GJ, Coleman WB. Somatic mutation analysis of human cancers: challenges in clinical practice. The Journal of Clinical Pharmacology. 2017 Oct 1;57(S10). View at Publisher View at Google Scholar
Gonzalez-Rivera M, Picornell AC, Alvarez EL, Martin M. A cross-sectional comparison of druggable mutations in primary tumors, metastatic tissue, circulating tumor cells, and cell-free circulating DNA in patients with metastatic breast cancer: the MIRROR study protocol. JMIR research protocols. 2016 Jul;5(3). View at Publisher View at Google Scholar
Tanaka M, Yoshimoto T, Nakamura T. A doubleâ€edged sword: The world according to Capicua in cancer. Cancer science. 2017 Dec;108(12):2319-25. View at Publisher View at Google Scholar
Guerini-Rocco E, Passaro A, Casadio C, De Luca VM, Guarize J, de Marinis F, Vacirca D, Barberis M. Acquired Resistance to Tyrosine Kinase Inhibitors in Nonâ€“Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasoundâ€“Guided Transbronchial Needle Aspiration Samples. Archives of pathology & laboratory medicine. 2018 Apr;142(4):465-73. View at Publisher View at Google Scholar
Guerini-Rocco E, Passaro A, Casadio C, De Luca VM, Guarize J, de Marinis F, Vacirca D, Barberis M. Acquired Resistance to Tyrosine Kinase Inhibitors in Nonâ€“Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasoundâ€“Guided Transbronchial Needle Aspiration Samples. Archives of pathology & laboratory medicine. 2018 Apr;142(4):465-73. View at Publisher View at Google Scholar
MartÃnez-JimÃ©nez F, Overington JP, Al-Lazikani B, Marti-Renom MA. Rational design of non-resistant targeted cancer therapies. Scientific reports. 2017 Apr 24;7:46632. View at Publisher View at Google Scholar
Grizzi F. Cancer heterogeneity and drug metabolism: what we know and what we need to know. View at Publisher View at Google Scholar
Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FC, Li J, Teh JL. A preexisting rare PIK3CAE545K subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling. Cancer discovery. 2018 Mar 1. View at Publisher View at Google Scholar
Venkatesan S, Rosenthal R, Kanu N, McGranahan N, Bartek J, Quezada SA, Hare J, Harris RS, Swanton C. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Annals of Oncology. 2018 Jan 8;29(3):563-72. View at Publisher View at Google Scholar
Snowden E, Porter W, Hahn F, Ferguson M, Tong F, Parker JS, Middlebrook A, Ghanekar S, Dillmore WS, Blaesius R. Immunophenotyping and transcriptomic outcomes in PDX-derived TNBC tissue. Molecular Cancer Research. 2016 Jan 1:molcanres-0286. View at Publisher View at Google Scholar
Cannataro VL, Gaffney SG, Stender C, Zhao ZM, Philips M, Greenstein AE, Townsend JP. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. Oncogene. 2018 May;37(18):2444. View at Publisher View at Google Scholar
Cannataro VL, Gaffney SG, Stender C, Zhao ZM, Philips M, Greenstein AE, Townsend JP. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. Oncogene. 2018 May;37(18):2444. View at Publisher View at Google Scholar
Hebbar N, Burikhanov R, Shukla N, Qiu S, Zhao Y, Elenitoba-Johnson KS, Rangnekar VM. A naturally generated decoy of the prostate apoptosis response-4 protein overcomes therapy resistance in tumors. Cancer research. 2017 Jun 16. View at Publisher View at Google Scholar
Peckys DB, Korf U, Wiemann S, de Jonge N. Liquid-phase electron microscopy of molecular drug response in breast cancer cells reveals irresponsive cell subpopulations related to lack of HER2 homodimers. Molecular biology of the cell. 2017 Nov 7;28(23):3193-202. View at Publisher View at Google Scholar
Vyse S, Howitt A, Huang PH. Exploiting synthetic lethality and network biology to overcome EGFR inhibitor resistance in lung cancer. Journal of molecular biology. 2017 Jun 16;429(12):1767-86. View at Publisher View at Google Scholar
Satas G, Raphael BJ. Tumor phylogeny inference using tree-constrained importance sampling. Bioinformatics. 2017 Jul 12;33(14):i152-60. View at Publisher View at Google Scholar
Botham RC, Roth HS, Book AP, Roady PJ, Fan TM, Hergenrother PJ. Small-molecule procaspase-3 activation sensitizes cancer to treatment with diverse chemotherapeutics. ACS central science. 2016 Jul 25;2(8):545-59. View at Publisher View at Google Scholar
Salk JJ, Schmitt MW, Loeb LA (2018) Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nature Reviews Genetics 19:269. View at Publisher View at Google Scholar
Venkatesan S, Swanton C, Taylor BS, Costello JF (2017) Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution. Cold Spring Harbor perspectives in medicine 13: 026617. View at Publisher View at Google Scholar
Prev 1 2 3 4 5 6 7 8 Next »

Journal of Next Generation Sequencing & Applications

+44 1250400002

Citations Report

Journal of Next Generation Sequencing & Applications : Citations & Metrics Report

Important Citations

VodÃ¡k D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E. Sample-Index Misassignment Impacts Tumour Exome Sequencing. Scientific reports. 2018 Mar 28;8(1):5307.

Tsongalis GJ, Coleman WB. Somatic mutation analysis of human cancers: challenges in clinical practice. The Journal of Clinical Pharmacology. 2017 Oct 1;57(S10).

Tanaka M, Yoshimoto T, Nakamura T. A doubleâ€edged sword: The world according to Capicua in cancer. Cancer science. 2017 Dec;108(12):2319-25.

MartÃnez-JimÃ©nez F, Overington JP, Al-Lazikani B, Marti-Renom MA. Rational design of non-resistant targeted cancer therapies. Scientific reports. 2017 Apr 24;7:46632.

Grizzi F. Cancer heterogeneity and drug metabolism: what we know and what we need to know.

Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FC, Li J, Teh JL. A preexisting rare PIK3CAE545K subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling. Cancer discovery. 2018 Mar 1.

Venkatesan S, Rosenthal R, Kanu N, McGranahan N, Bartek J, Quezada SA, Hare J, Harris RS, Swanton C. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Annals of Oncology. 2018 Jan 8;29(3):563-72.

Snowden E, Porter W, Hahn F, Ferguson M, Tong F, Parker JS, Middlebrook A, Ghanekar S, Dillmore WS, Blaesius R. Immunophenotyping and transcriptomic outcomes in PDX-derived TNBC tissue. Molecular Cancer Research. 2016 Jan 1:molcanres-0286.

Cannataro VL, Gaffney SG, Stender C, Zhao ZM, Philips M, Greenstein AE, Townsend JP. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. Oncogene. 2018 May;37(18):2444.

Cannataro VL, Gaffney SG, Stender C, Zhao ZM, Philips M, Greenstein AE, Townsend JP. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. Oncogene. 2018 May;37(18):2444.

Hebbar N, Burikhanov R, Shukla N, Qiu S, Zhao Y, Elenitoba-Johnson KS, Rangnekar VM. A naturally generated decoy of the prostate apoptosis response-4 protein overcomes therapy resistance in tumors. Cancer research. 2017 Jun 16.

Peckys DB, Korf U, Wiemann S, de Jonge N. Liquid-phase electron microscopy of molecular drug response in breast cancer cells reveals irresponsive cell subpopulations related to lack of HER2 homodimers. Molecular biology of the cell. 2017 Nov 7;28(23):3193-202.

Vyse S, Howitt A, Huang PH. Exploiting synthetic lethality and network biology to overcome EGFR inhibitor resistance in lung cancer. Journal of molecular biology. 2017 Jun 16;429(12):1767-86.

Satas G, Raphael BJ. Tumor phylogeny inference using tree-constrained importance sampling. Bioinformatics. 2017 Jul 12;33(14):i152-60.

Botham RC, Roth HS, Book AP, Roady PJ, Fan TM, Hergenrother PJ. Small-molecule procaspase-3 activation sensitizes cancer to treatment with diverse chemotherapeutics. ACS central science. 2016 Jul 25;2(8):545-59.

Salk JJ, Schmitt MW, Loeb LA (2018) Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nature Reviews Genetics 19:269.

Venkatesan S, Swanton C, Taylor BS, Costello JF (2017) Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution. Cold Spring Harbor perspectives in medicine 13: 026617.

Journal Highlights

Journal Flyer

Citations Report

Journal of Next Generation Sequencing & Applications : Citations & Metrics Report

Important Citations

VodÃ¡k D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E. Sample-Index Misassignment Impacts Tumour Exome Sequencing. Scientific reports. 2018 Mar 28;8(1):5307.

Tsongalis GJ, Coleman WB. Somatic mutation analysis of human cancers: challenges in clinical practice. The Journal of Clinical Pharmacology. 2017 Oct 1;57(S10).

Tanaka M, Yoshimoto T, Nakamura T. A doubleâ€edged sword: The world according to Capicua in cancer. Cancer science. 2017 Dec;108(12):2319-25.

MartÃ­nez-JimÃ©nez F, Overington JP, Al-Lazikani B, Marti-Renom MA. Rational design of non-resistant targeted cancer therapies. Scientific reports. 2017 Apr 24;7:46632.

Grizzi F. Cancer heterogeneity and drug metabolism: what we know and what we need to know.

Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FC, Li J, Teh JL. A preexisting rare PIK3CAE545K subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling. Cancer discovery. 2018 Mar 1.

Venkatesan S, Rosenthal R, Kanu N, McGranahan N, Bartek J, Quezada SA, Hare J, Harris RS, Swanton C. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Annals of Oncology. 2018 Jan 8;29(3):563-72.

Snowden E, Porter W, Hahn F, Ferguson M, Tong F, Parker JS, Middlebrook A, Ghanekar S, Dillmore WS, Blaesius R. Immunophenotyping and transcriptomic outcomes in PDX-derived TNBC tissue. Molecular Cancer Research. 2016 Jan 1:molcanres-0286.

Cannataro VL, Gaffney SG, Stender C, Zhao ZM, Philips M, Greenstein AE, Townsend JP. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. Oncogene. 2018 May;37(18):2444.

Cannataro VL, Gaffney SG, Stender C, Zhao ZM, Philips M, Greenstein AE, Townsend JP. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. Oncogene. 2018 May;37(18):2444.

Hebbar N, Burikhanov R, Shukla N, Qiu S, Zhao Y, Elenitoba-Johnson KS, Rangnekar VM. A naturally generated decoy of the prostate apoptosis response-4 protein overcomes therapy resistance in tumors. Cancer research. 2017 Jun 16.

Peckys DB, Korf U, Wiemann S, de Jonge N. Liquid-phase electron microscopy of molecular drug response in breast cancer cells reveals irresponsive cell subpopulations related to lack of HER2 homodimers. Molecular biology of the cell. 2017 Nov 7;28(23):3193-202.

Vyse S, Howitt A, Huang PH. Exploiting synthetic lethality and network biology to overcome EGFR inhibitor resistance in lung cancer. Journal of molecular biology. 2017 Jun 16;429(12):1767-86.

Satas G, Raphael BJ. Tumor phylogeny inference using tree-constrained importance sampling. Bioinformatics. 2017 Jul 12;33(14):i152-60.

Botham RC, Roth HS, Book AP, Roady PJ, Fan TM, Hergenrother PJ. Small-molecule procaspase-3 activation sensitizes cancer to treatment with diverse chemotherapeutics. ACS central science. 2016 Jul 25;2(8):545-59.

Salk JJ, Schmitt MW, Loeb LA (2018) Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nature Reviews Genetics 19:269.

Venkatesan S, Swanton C, Taylor BS, Costello JF (2017) Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution. Cold Spring Harbor perspectives in medicine 13: 026617.

Journal Highlights

Journal Flyer

Tanaka M, Yoshimoto T, Nakamura T. A doubleâ€edged sword: The world according to Capicua in cancer. Cancer science. 2017 Dec;108(12):2319-25.

MartÃnez-JimÃ©nez F, Overington JP, Al-Lazikani B, Marti-Renom MA. Rational design of non-resistant targeted cancer therapies. Scientific reports. 2017 Apr 24;7:46632.